foslevodopa/foscarbidopa vs Levodopa-carbidopa intestinal gel
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: dopamine precursor · full Parkinson's Disease pipeline
foslevodopa/foscarbidopa · Vyalev
Marketed by AbbVie
NCT04380142 · Phase 3 · completed
The trial randomized 145 participants to active treatment or an active comparator, with participants, clinicians, investigators, and outcome assessors quadruple-blinded. The primary clinical endpoint was met: least-squares mean improvement in “On” time was 2.72 hours with ABBV-951 versus 0.97 hours with oral carbidopa/levodopa, a difference of 1.75 hours (95% CI 0.46–3.05; p=0.0083).
Reported efficacy
Change From Baseline to Week 12 of the Double-Blind Treatment Period in Average Daily Normalized "On" Time Without Troublesome Dyskinesia (Baseline (Week 0) up to Week 12 of the double-blind treatment period): Change From Baseline to Week 12 of the Double-Blind Treatment Period in Average Daily Normalized "On" Time Without Troublesome Dyskinesia (Baseline (Week 0) up to Week 12 of the double-blind treatment period): ABBV-951 + Placebo for LD/CD 2.72 hours (Standard Error 0.52) vs LD/CD + Placebo for ABBV-951 0.97 hours (Standard Error 0.5) (met)
Result source: NCT04380142
Levodopa-carbidopa intestinal gel · Duopa
Marketed by AbbVie
NCT00335153 · Phase 3 · completed
This was a 354-participant, open-label, single-group study with no randomization, blinding, or comparator arm. Its primary outcomes focused on safety and device complications, and there was no formal controlled primary efficacy comparison, so the reported secondary improvements do not establish treatment efficacy.
Reported efficacy
Change From Baseline to Week 12 in Average Daily Normalized "Off" Time (Baseline, Week 12): Change From Baseline to Week 12 in Average Daily Normalized "Off" Time (Baseline, Week 12): LCIG + Placebo Capsules -4.04 hours (Standard Error 0.65) vs Placebo Gel + Levodopa-Carbidopa Capsules -2.14 hours (Standard Error 0.66) (met)
Result source: NCT00357994
Results for Parkinson's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | foslevodopa/foscarbidopa | Levodopa-carbidopa intestinal gel |
|---|---|---|
| OFF time, change | -2.8 vs -1.0vs LD/CDNCT04380142 | -4.0 vs -2.1vs Levodopa-Carbidopa CapsulesNCT003579942 other results
|
| ON time without troublesome dyskinesia, change | 2.7 vs 1.0vs LD/CDNCT04380142 | 4.1 vs 2.2vs Levodopa-Carbidopa CapsulesNCT003579941 other result
|
| UPDRS Part III, change | —Not posted · NCT04379050 | -1.5 vs -2.9vs Levodopa-Carbidopa CapsulesNCT003579942 other results
|
| MDS-UPDRS Part II, change | -2.6 vs -1.1vs LD/CDNCT04380142 | —Not posted · NCT01960842 |
OFF time, change
- foslevodopa/foscarbidopa
- -2.8 vs -1.0vs LD/CDNCT04380142
- Levodopa-carbidopa intestinal gel
- -4.0 vs -2.1vs Levodopa-Carbidopa CapsulesNCT00357994
2 other results
- -4.0 vs -2.1 NCT00660387
- -2.2 vs 0.2 NCT02799381
ON time without troublesome dyskinesia, change
- foslevodopa/foscarbidopa
- 2.7 vs 1.0vs LD/CDNCT04380142
- Levodopa-carbidopa intestinal gel
- 4.1 vs 2.2vs Levodopa-Carbidopa CapsulesNCT00357994
1 other result
- 3.1 vs -0.1 NCT02799381
UPDRS Part III, change
- foslevodopa/foscarbidopa
- —Not posted · NCT04379050
- Levodopa-carbidopa intestinal gel
- -1.5 vs -2.9vs Levodopa-Carbidopa CapsulesNCT00357994
2 other results
- -4.9 vs -0.9 NCT02799381
- -1.5 vs -2.9 NCT00660387
MDS-UPDRS Part II, change
- foslevodopa/foscarbidopa
- -2.6 vs -1.1vs LD/CDNCT04380142
- Levodopa-carbidopa intestinal gel
- —Not posted · NCT01960842
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
2 other shared endpoints and safety
Coverage. foslevodopa/foscarbidopa: 6 of 6 rows · Levodopa-carbidopa intestinal gel: 6 of 6 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | foslevodopa/foscarbidopa Rows use multiple source trials | Levodopa-carbidopa intestinal gel Rows use multiple source trials |
|---|---|---|
| OFF Time absolute change · hours No placebo or comparator arm | -2.4 hours @ 6wka,b,c NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 show 2 more doses-2.36 hours @ 6wkhigh dose NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 -2.43 hours @ 6wklow dose NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 | 2.61 hours @ 6wkb,c NCT01960842 · Phase 3 · registry result, not featured evidence |
| PDSS-2 Total absolute change · score | -7.92 vs -2.52 LD/CD score @ 12wkb,c,d NCT04380142 · Phase 3 · Parkinson's Disease · phase 3 | -7.41 vs -8.98 Optimized Medical Treatment score @ 26wkb,c,d NCT02549092 · Phase 3 · registry result, not featured evidence |
| Dropout rate | — NCT04380142 · Phase 3 · Parkinson's Disease · phase 3 show 3 more results—ABBV-951 All Participants NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 42.5%high dose NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 35.9%low dose NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 | 8.5%e NCT00335153 · Phase 3 show 13 more results5.4% NCT00357994 · Phase 3 43.2%Duodopa Naïve NCT00141518 · Phase 4 · registry result, not featured evidence 27.3%Duodopa Non-naïve < 2 Years NCT00141518 · Phase 4 · registry result, not featured evidence 33.3%Duodopa Non-naïve ≥ 2 Years NCT00141518 · Phase 4 · registry result, not featured evidence 15.6% NCT02549092 · Phase 3 · registry result, not featured evidence 44.7% NCT00660673 · Phase 3 · registry result, not featured evidence 10.7% NCT02799381 · Phase 3 · registry result, not featured evidence — NCT01736176 · Phase 3 · registry result, not featured evidence 9.7% NCT01960842 · Phase 3 · registry result, not featured evidence — NCT00360568 · Phase 3 · registry result, not featured evidence 5.4% NCT00660387 · Phase 3 · registry result, not featured evidence 37.5% NCT01479127 · Phase 2 · registry result, not featured evidence — NCT02448914 · Phase 1 · registry result, not featured evidence · Parkinson's Disease · phase 1 |
| Discontinued due to AEs | — NCT04380142 · Phase 3 · Parkinson's Disease · phase 3 show 3 more results—ABBV-951 All Participants NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 22.1%high dose NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 17.6%low dose NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 | 1.4%e NCT00335153 · Phase 3 show 13 more results2.7% NCT00357994 · Phase 3 18.9%Duodopa Naïve NCT00141518 · Phase 4 · registry result, not featured evidence 22.7%Duodopa Non-naïve < 2 Years NCT00141518 · Phase 4 · registry result, not featured evidence 11.1%Duodopa Non-naïve ≥ 2 Years NCT00141518 · Phase 4 · registry result, not featured evidence 4.4% NCT02549092 · Phase 3 · registry result, not featured evidence 32.1% NCT00660673 · Phase 3 · registry result, not featured evidence 3.6% NCT02799381 · Phase 3 · registry result, not featured evidence — NCT01736176 · Phase 3 · registry result, not featured evidence 3.2% NCT01960842 · Phase 3 · registry result, not featured evidence — NCT00360568 · Phase 3 · registry result, not featured evidence 2.7% NCT00660387 · Phase 3 · registry result, not featured evidence — NCT01479127 · Phase 2 · registry result, not featured evidence — NCT02448914 · Phase 1 · registry result, not featured evidence · Parkinson's Disease · phase 1 |
| Serious AEs | 8.1% NCT04380142 · Phase 3 · Parkinson's Disease · phase 3 show 3 more results25.8%ABBV-951 All Participants NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 27.4%high dose NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 24.4%low dose NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 | 30.5%e NCT00335153 · Phase 3 show 13 more results13.5% NCT00357994 · Phase 3 66.7%Duodopa Naïve NCT00141518 · Phase 4 · registry result, not featured evidence 77.3%Duodopa Non-naïve < 2 Years NCT00141518 · Phase 4 · registry result, not featured evidence 77.8%Duodopa Non-naïve ≥ 2 Years NCT00141518 · Phase 4 · registry result, not featured evidence 20.9% NCT02549092 · Phase 3 · registry result, not featured evidence 60.7% NCT00660673 · Phase 3 · registry result, not featured evidence 7.1% NCT02799381 · Phase 3 · registry result, not featured evidence 20.5% NCT01736176 · Phase 3 · registry result, not featured evidence 12.9% NCT01960842 · Phase 3 · registry result, not featured evidence 22.6% NCT00360568 · Phase 3 · registry result, not featured evidence 13.5% NCT00660387 · Phase 3 · registry result, not featured evidence 16.7% NCT01479127 · Phase 2 · registry result, not featured evidence 0% NCT02448914 · Phase 1 · registry result, not featured evidence · Parkinson's Disease · phase 1 |
| Most frequent reported AEs | infusion site erythema 27% infusion site pain 25.7% infusion site cellulitis 17.6% NCT04380142 · Phase 3 · Parkinson's Disease · phase 3 show 3 more resultsinfusion site erythema 52% infusion site nodule 28.7% infusion site oedema 19.3% NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 high dose infusion site erythema 55.8% infusion site nodule 30.1% infusion site oedema 24.8% NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 low dose infusion site erythema 48.9% infusion site nodule 27.5% infusion site cellulitis 19.1% NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 | show 13 more resultsconstipation 22.2% depression 19.4% device dislocation 19.4% NCT00141518 · Phase 4 · registry result, not featured evidence device dislocation 36.4% excessive granulation tissue 31.8% device related infection 27.3% NCT00141518 · Phase 4 · registry result, not featured evidence blood homocysteine increased 33.3% device dislocation 27.8% constipation 22.2% NCT00141518 · Phase 4 · registry result, not featured evidence stoma site pain 14% abdominal pain 11.6% stoma site infection 11.6% NCT02549092 · Phase 3 · registry result, not featured evidence vitamin b6 decreased 27.1% blood homocysteine increased 22.5% postoperative wound infection 21% NCT00660673 · Phase 3 · registry result, not featured evidence fall 21.4% procedural pain 10.7% abdominal pain 7.1% NCT02799381 · Phase 3 · registry result, not featured evidence procedural pain 33.3% stoma site infection 28.2% stoma site pain 23.1% NCT01736176 · Phase 3 · registry result, not featured evidence incision site pain 41.9% excessive granulation tissue 32.3% constipation 19.4% NCT01960842 · Phase 3 · registry result, not featured evidence incision site erythema 29% fall 21% vitamin b6 decreased 21% NCT00360568 · Phase 3 · registry result, not featured evidence complication of device insertion 54.1% abdominal pain 51.4% nausea 29.7% NCT00660387 · Phase 3 · registry result, not featured evidence dyskinesia 33.3% fall 33.3% anaemia 16.7% NCT01479127 · Phase 2 · registry result, not featured evidence cold sweat 9.1% diarrhoea 9.1% headache 9.1% NCT02448914 · Phase 1 · registry result, not featured evidence · Parkinson's Disease · phase 1 |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dAssessment timepoints differ: 12 weeks versus 26 weeks.
- ePopulation comparability has not been reviewed for 13 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
foslevodopa/foscarbidopa
show 17 more results
show 17 more results
show 29 more results
show 29 more results
show 29 more results
show 29 more results
show 14 more results
+ 2 further endpoints in the CSV export.
Levodopa-carbidopa intestinal gel
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
+ 329 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: foslevodopa/foscarbidopa's landscape · Levodopa-carbidopa intestinal gel's landscape